153 related articles for article (PubMed ID: 17574728)
1. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Di Lorenzo G
Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
[No Abstract] [Full Text] [Related]
2. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Strumberg D
J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
[No Abstract] [Full Text] [Related]
4. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
5. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Larkin J; Gore M
Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
[No Abstract] [Full Text] [Related]
6. Editorial comment.
Rini BI; Shah SN
Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
[No Abstract] [Full Text] [Related]
7. Editorial comment.
Vaishampayan U
Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
[No Abstract] [Full Text] [Related]
8. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
9. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
10. [Renal cell carcinoma].
Oya M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
[No Abstract] [Full Text] [Related]
11. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
12. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
13. Renal-cell carcinoma--molecular pathways and therapies.
Brugarolas J
N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
[No Abstract] [Full Text] [Related]
14. Therapy for metastatic RCC--questions remain.
Breau RH; Leibovich BC
Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
[No Abstract] [Full Text] [Related]
15. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Vira MA; Novakovic KR; Pinto PA; Linehan WM
BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
[No Abstract] [Full Text] [Related]
16. [Molecular targeted therapy for renal cell carcinoma].
Kakehi Y
Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
[No Abstract] [Full Text] [Related]
17. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
18. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
19. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
20. [New drugs; sunitinib and sorafenib].
van Bronswijk H; Dubois EA; Osanto S; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]